Triglycerides and cardiovascular disease

  title={Triglycerides and cardiovascular disease},
  author={B{\o}rge Gr{\o}nne Nordestgaard and Anette Varbo},
  journal={The Lancet},

Figures from this paper

Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk

This study shows that elevated triglyceride (TG) levels, reduced high-density lipoprotein cholesterol (HDL-C), and the existence of obesity/insulin resistance and diabetes may be important metabolic factors that determine statin residual CVD risk.

Triglycerides and residual risk.

Evidence suggests higher triglycerides are a marker of CVRisk and may help identify patients who benefit from intensification of therapy and treatment with high-dose EPA may be of benefit in high-risk patients with hypertriglyceridemia to reduce CVRisks.

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk

Among the new LDL-lowering therapies, PCSK9 inhibitors appear the most promising class and apolipoprotein(a), and triglyceride-rich lipoproteins, and the strategies to modulate HDL metabolism are described.

Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment

The use of statins, fibrates, APOC3 inhibitors, PCSK9 inhibitors, and omega-3 fatty acids to reduce RC levels in the plasma may provide long-term benefits, and more studies on appropriate treatments of elevated RC are urgently needed.

Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management.

Triglycerides as Residual Risk for Atherosclerotic Cardiovascular Disease.

  • H. Ohmura
  • Biology, Medicine
    Circulation journal : official journal of the Japanese Circulation Society
  • 2019
Elevated serum TG levels are significantly associated with an increased risk of first major cardiovascular events (MACE) in patients with CAD treated with optimal medical therapy, indicating a possible pathogenetic role of these lipids in atherosclerosis rather than merely serving as biomarkers of disease risk.

Addressing dyslipidemic risk beyond LDL-cholesterol

Rare genetic variants that lower triglyceride levels via activation of lipolysis and associate with reduced CVD suggest new approaches to treating dyslipidemia.

Hypertriglyceridaemia and risk of coronary artery disease

Findings from several large studies indicate that elevated levels of triglycerides or, more specifically, triglyceride-rich lipoproteins and their remnants, are independently associated with increased risk of CVD.

Remnant Cholesterol and Triglyceride-Rich Lipoproteins in Atherosclerosis Progression and Cardiovascular Disease.

The main finding was that achieved concentrations of non-HDL cholesterol and achieve concentrations of triglycerides were closely associated with coronary atheroma progression and regression, irrespective of achieved concentrationsof low-density lipoprotein (LDL) cholesterol, C-reactive protein concentration, and diabetes mellitus status.



Triglycerides and Heart Disease: Still a Hypothesis?

The purpose of this article is to review the basic and clinical science relating plasma triglycerides and cardiovascular disease and to suggest new and creative approaches to understanding the relationship of triglyceride and heart disease.

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

Bezafibrate was safe and effective in elevating HDL-C levels and lowering triglycerides and an overall trend in a reduction of the incidence of primary end points was observed.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter, there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels.

Nonfasting hyperlipidemia and cardiovascular disease.

The results highlight the need for randomized double-blind trials of new and established drugs to reduce nonfasting triglycerides and remnant lipoprotein cholesterol, with the ultimate aim of reducing risk of cardiovascular disease and early death.

Common variants associated with plasma triglycerides and risk for coronary artery disease

It is suggested that triglyceride-rich lipoproteins causally influence risk for CAD, and the strength of a polymorphism's effect on triglyceride levels is correlated with the magnitude of its effect on CAD risk.

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.

The results of this study suggest that both elevating HDL and lowering LDL cholesterol levels are effective in the primary prevention of CHD.

Postprandial hypertriglyceridemia as a coronary risk factor.